Sequenom is looking to its deal with Quest Diagnostics and a new noninvasive prenatal test, VisibiliT, which it will launch in Europe for trisomies 21 and 18, to help drive new revenue growth, company officials said this week. The San Diego-based firm’s testing volumes in the third quarter of 2014 declined more than 3 percent compared to the third quarter of 2013 to 46,600 patient samples. MaterniT21 Plus tests remained stable year over year at around 38,500, although they declined by 2,300 tests sequentially. During a conference call discussing Sequenom’s third quarter earnings, CEO Bill Welch also provided an update on the firm’s VisibiliT test, which is geared toward women at average risk for fetal aneuploidy, as well as its patent lawsuits, and its agreement with Quest. Read more.
Prenatal Information Research Consortium 